首页> 外文期刊>The Journal of Allergy and Clinical Immunology >Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy
【24h】

Predominant Api m 10 sensitization as risk factor for treatment failure in honey bee venom immunotherapy

机译:蜜蜂毒液免疫治疗中主要的Api m 10致敏作用是治疗失败的危险因素

获取原文
获取原文并翻译 | 示例
           

摘要

Background: Component resolution recently identified distinct sensitization profiles in honey bee venom (HBV) allergy, some of which were dominated by specific IgE to Api m 3 and/or Api m 10, which have been reported to be underrepresented in therapeutic HBV preparations.
机译:背景:成分分离度最近在蜜蜂毒(HBV)过敏中发现了不同的致敏特征,其中一些由对Api m 3和/或Api m 10的特异性IgE所占主导,据报道在治疗性HBV制剂中这些代表不足。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号